bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 3187: Utility of serum p53 antibodies in patients with various types of malignant tumors
Authors: Hagiwara Nobutoshi , Miyashita Masao , Yamashita Naoyuki , Iida Shinya , Nomura Tsutomu , Makino Hiroshi , Okawa Keiichi , Takahashi Ken , Akagi Ichiro , Shinozuka Eriko , Fujita Itsuro , Kanazawa Yoshiichi , Sakurazawa Nobuyuki , Onodera Hiroyuki , Uchida Eiji 
Published: June 2012

Abstract
Background: Circulating anti-p53 antibody(p53-Ab) in blood can be detected in various cancers. Serum p53-Ab has been applied as a tumor marker in clinical practice. We studied the clinical significance of p53-Ab in patients with esophageal, colorectal, and breast carcinoma.
Methods: p53-Ab in serum was measured with Enzyme-linked immunosorvent assay (ELISA) before treatment in 51 patients with esophageal carcinoma, 54 patients with colorectal carcinoma, and 84 patients with breast carcinoma. clinical and pathological features of these cancers
The association between clinicopathological factors of these cancers and the level of p53-Ab in serum was evaluated.
Results: Twenty-one(41%) of 51 patients with esophageal cancer, 23 (42%) of 54 with colorectal cancer, and 26 (30%) of 84 with breast cancer were diagnosed as p53-Ab positive according to the Manufacture's cut-off value. p53-Abs in serum were observed in all these cancer patients with earlier stage. Positive p53-Ab cases in esophageal, colorectal, and breast cancer in stage I were 33%, 25%, and 35%, respectively. There was no correlation between the positive cases and the age, sex, lymph node metastases, distant metastases, or tumor stage.
Conclusion: This study showed that p53-Ab in serum was frequently detected in patients with esophageal, colorectal, and breast cancer. p53-Ab can be a promising tumor marker for the early detection of these cancers.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3187. doi:10.1158/1538-7445.AM2011-3187
Abstract 3191: Immune cell bound MUC16 (CA125): A novel diagnostic marker for ovarian cancer
Authors: Belisle Jennifer A. , Felder Mildred , Kapur Arvinder , Tyler Chanel T. , Connor Joseph P. , Patankar Manish S. 
Published: June 2012

Abstract
MUC16 is a cell surface mucin expressed at high levels by epithelial ovarian cancer cells. Following proteolytic cleavage, cell surface MUC16 (csMUC16) is shed (sMUC16) in the extracellular milieu and is detected in the serum of cancer patients as the tumor marker CA125. csMUC16 acts as an adhesion molecule and facilitates peritoneal metastasis of ovarian tumors. Both sMUC16 and csMUC16 also protect cancer cells from cytotoxic responses of natural killer (NK) cells. In a previous study, we demonstrated that sMUC16 binds to a specific subset of NK cells. Here, we demonstrate that in addition to NK cells, sMUC16 also binds to B cells and monocytes isolated from the peripheral circulation and the peritoneal fluid. I-type lectin, Siglec-9, is identified as the sMUC16 receptor on these immune cells. The inhibitory receptor Siglec-9 is expressed on approximately 30-40% of CD16pos/CD56dim NK cells, 20-30% of B cells and &gt;95% of monocytes. sMUC16 binds to the majority of the Siglec-9pos NK cells, B cells and monocytes. sMUC16 is released from the immune cells following neuraminidase treatment. While sMUC16 binds to Siglec-9, it has no affinity for another I-type lectin, Siglec-7. Experiments with Siglec-9 transfected Jurkat cells and monocytes isolated from healthy donors demonstrate that immune cells can bind to ovarian tumor cells via Siglec-9-csMUC16 interaction. sMUC16-Siglec-9 binding is a high affinity and event and the mucin is detected on the surface of the patient-derived immune cells even after the cells have been cultured in vitro in media that does not contain any sMUC16. The MUC16 mucin is also expressed by the human decidua and higher circulating levels of this molecule (measured as CA125) are detected in peripheral circulation of pregnant women. Flow cytometry analysis of immune cells from pregnant women indicates that MUC16 can be detected on the surface of specific subsets of immune cells even when the serum CA125 levels are very low or undetectable. Furthermore, we have observed that sMUC16 is detected on distinct subsets of NK cells of women with preeclampsia as compared to healthy pregnant women and patients with ovarian tumors. Our on-going studies are focused on monitoring sMUC16 binding to specific subsets of immune cells to determine if this information can be used to devise a novel assay for the diagnosis and monitoring of ovarian tumors.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3191. doi:10.1158/1538-7445.AM2011-3191
Abstract 3200: HPV status influences the survival of HNSCC patients: A consideration for the TNM staging system
Authors: Ruiz-Fullana Francisco J. , Velez-Reyes German , Garcia Aurian , Trinidad-Pinedo Juan , Báez Adriana 
Published: June 2012

Abstract
Objective: Head and neck cancers are a heterogeneous group of malignancies, affecting various sites with differing prognoses. Accurate and reliable stratification of head and neck squamous cell carcinomas (HNSCC) for prediction of outcomes continues to be very challenging. The TNM staging system for HNSCCs is an important tool for reporting and defining treatment. However, there is increasing evidence for the role of human papillomavirus type 16 (HPV) in the pathogenesis of oropharyngeal SCC and predictive of a better prognoses. We have shown that Puerto Ricans have a high percentage of HPV-positive HNSCC particularly in the larynx. The goal of this study is to evaluate the relevance of HPV-positivity in the prediction of HNSCC patient's outcome together with the TNM staging system.
Methods: Patients presenting to our department with HNSCC until 2005 and whose treatment was surgical were in included in this study. Survival trends (Kaplan-Meier survival curves) were used to evaluate survival differences according to anatomic subsite, HPV status, risk factors and clinicopathological characteristics.
Results: One hundred eight -four patients were included in the study with a median follow-up of 59 months. Distribution according to specific tumor sites was 86 (46.7%) in the larynx; 70 (38%) in the oral cavity, 16 (8.7%) in the oropharynx, and 12 (6.5%) in the hypopharynx. The highest incidence of HPV – positive was in the oropharynx (67%). Multivariate analysis showed that HPV had an independent prognostic effect on the overall survival after adjusting other confounding factors such as histological grade, TNM stage and tobacco usage. The patient of HPV-positive laryngeal SCC showed a statistically longer absolute (p&lt;0.05) and relapse-free (p=0.001) 5-year survival time than the HPV-negative group. However, the difference between HPV- positive and HPV-negative oral cavity tumors was less prominent. Patients younger than 30 years of age presented with advanced tumor stages. Failure pattern in younger age SCC patient may be attributable to biologic behavior.
Conclusion: HPV status on HNSCC patients is a determinant factor in the survival of such patients dependent on tumor site and should be considered in addition to the actual TNM staging system.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3200. doi:10.1158/1538-7445.AM2011-3200
Abstract 3214: Identification of a new marker of hepatocellular carcinoma with HBV in female
Authors: Chen-Shiou Wu , Chia-Jui Yen , Chung-Yi Wu , Yung-Luen Yu 
Published: June 2012

Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Early prognostic markers are needed to allow effective treatments and prevent HCC from developing. Serum alpha-fetoprotein, the currently used clinical marker, is elevated in only approximately 60% of HCC patients; therefore, the identification of additional markers is expected to have significant public health impact. The objective of our study was to discover and validate serum glycoprotein biomarkers in HCC using glycan microarray. We used glycan microarray for quantitative comparison of 188 in serum samples (155 HCC cases, and 33 normal). To explored the diagnostic possibilities of antibody changes as a marker for HCC. In addition, we compared the accuracy of using this serum patterns with the conventional AFP biomarkers for HCC patients. we have shown that the new biomarker with glycan microarray can be useful in the screening of serum biomarkers for HCC. The serum concentration of anti-disialogangliosides in HCC patients was significantly higher than in normal. Besides, in female the anti-gangliosides antibody in HCC patients was significantly higher than in normal. The marker candidates have good prediction sensitivity than AFP in this population. The glycan microarray thus provides a new platform for use to monitor the immune response to carbohydrate epitopes during the course of cancer progression. Additional study of its utility for diagnosis and follow-up is recommended.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3214. doi:10.1158/1538-7445.AM2011-3214
Abstract 3217: Influence of PIK3CA mutation and methylation of BNIP3, p16 and Dkk1 on outcome in colorectal cancer
Authors: Iida Satoru , Kato Shunsuke , Ishiguro Megumi , Ishikawa Toshiaki , Kobayashi Hirotoshi , Higuchi Tetsuro , Enomoto Masayuki , Uetake Hiroyuki , Sugihara Kenichi 
Published: June 2012

Abstract
Many studies have exhibited that EGFR pathway triggers a complex program of intracellular signals ant is activated in various human cancers. Among the oncogenic abnormalities that affect this pathway, mutation of PIK3CA and K-Ras mutation are reported to appear most frequently in colorectal cancer (CRC). Epigenetic alteration such as promoter hypermethylation of gene, as well as genetic abnormality such as gene mutation, occurs frequently during the pathogenesis of human cancers. Recent studies exhibit the increasing observations that both epigenetic and genetic changes combine to determine the phenotype of cancer. However, the relationship between PIK3CA and KRAS mutations and methylation status remains uncertain in CRC. Therefore, we examined the mutation of PIK3CA and KRAS and the methylation status of BNIP3, p16 and hMLH1 in CRC and analyzed the influence of the combination of mutation and methylation on prognosis in CRC patients. Tissue samples from 166 CRC patients who underwent surgical resection were examined. The sequences of exons 9 and 20 of PIK3CA and exon 1 of K-Ras were determined by direct sequencing, and the methylation status by MethyLight, using genomic DNA extracted from paraffin-embedded blocks. Correlation between these factors and clinicopathological findings/patients survival were examined. As a result, mutations of PIK3CA and KRAS were found in 12% and 31% of the specimens respectively, and methylations of BNIP3, p16 and hMLH1 in 58%, 33% and 21% respectively. Mutation and methylation of each gene had no correlation with any clinicopathological factor. Patients with PIK3CA mutation and/or two or three methylations had significantly shorter disease-specific survival than those without both mutation and methylation (p=0.0082, Log-rank test). Classifying CRC based on PIK3CA mutation and BNIP3, p16 and hMLH1 methylation status may be a clinically powerful predictor of patient outcome.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3217. doi:10.1158/1538-7445.AM2011-3217
Abstract 3218: High pathological CR rate and low recurrence rate was observed in liver metastasis of colorectal cancer after preoperative bevacizumab plus FOLFOX therapy
Authors: Uetake Hiroyuki , Ishikawa Toshiaki , Mitsunori Yusuke , Tanaka Shinji , Arii Shigeki , Sugihara Kenichi 
Published: June 2012

Abstract
[Background] We reported the effectiveness of intraoperative contrast-enhanced ultrasonography using perflubutane (SONAZOIDTM) for complete resection of liver metastasis from colorectal cancer (CRC) after Bevacizumab (Bmab)+FOLFOX therapy (Annual meeting of AACR, 2010). In this study, we report pathological CR (pCR) rate of resected liver tumors and recurrence rate of disappeared lesions that were not resected. [Material and methods] Sixteen patients of advanced CRC with liver metastasis only (no extrahepatic lesion) were treated with Bmab+FOLFOX therapy. Response rate of chemotherapy was 81%. Among the 16 patients, 8 (50%) were underwent liver resection after chemotherapy. We study 6 of the 8 patients, who were followed up longer than a year (20-33 months). [Result] By CT angiography, 47 liver metastases were detected before chemotherapy. By intraoperative contrast-enhanced ultrasonography, 26 liver tumors were detected and resected. In histological examination, 11 (42%) were without viable cancer cell (pCR). Among 21 lesions that were not detected by intraoperative ultrasound and not resected, only 2 lesions were re-detected in follow up period and both lesion were resected. [Conclusion] High pCR rate and low recurrence rate was observed in liver metastasis of colorectal cancer after preoperative Bmab + FOLFOX therapy. Contrast-enhanced ultrasonography was effective for complete resection of liver metastases, as well as low recurrence rate of disappeared lesion after chemotherapy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3218. doi:10.1158/1538-7445.AM2011-3218
Abstract 3222: Pre-clinical toxicology and pharmacology of 4-hydroperoxyifosfamide (4-HOOI) and L-lysine salt
Authors: Morgan Lee R. , Rodgers Andrew H. , Struck Robert F. , Jursic Branko S. , Bastian Gerard , Waud William R. , Papiagiannis Chris , Papiagiannis Chris 
Published: June 2012

Abstract
HOOI is a hydroperoxy-derivative of ifosfamide (IFOS) and a pro-drug of isophosphoramide mustard (IPM) [the active metabolite of IFOS] – a bi-functional alkylator that cross-links with G/C DNA base sequences resulting in irreparable inter-strand DNA cross-linking and cell death. HOOI has been an unstable laboratory curiosity for years; however, HOOI.L-lysine is a stable salt complex that has allowed the development of HOOI for clinical trials. HOOI spontaneously releases acrolein and chloroacetaldehyde in situ in cancer cells not extracellular in the general circulation (as does IFOS) and has not been associated with cystitis, renal tubular necrosis and/or CNS toxicity.
HOOI has been screened in 20+ human xenograft tumor and murine tumor models and has significantly improved %ILS in intracranially implanted human xenografts – MX-1, U251; ZR-75-1 and in P399/CPA leukemia vs. IFOS and IPM. The U251 data (%ILS – 84+) is impressive considering – BCNU produced a 72% ILS. The ZR-75-1 breast cancer had a %ILS – 83.
Bone marrow failure was the DLT in mice – LD10 100 mg/kg (for M/F). Dogs (M/F) were treated with 10, 15, 20 and 30 mg/kg. For both sexes, the LD10 was calculated to be 17.2, while the LD50 was calculated to be 17.3 mg/kg. PK values in dogs revealed the following profile for groups dosed with 30 mg/kg: AUC0- t = 1.53 (mg h/L), T1/2α = 0.93 (h), T1/2β = 6.1 (h) & CL = 19.5 (L/ h) [a two compartment model]. The AUC was linear for the 10 and 30 mg/kg doses. HOOI did not generate any detectable plasma chloroacetaldehyde vs. IFOS (2.12 µg/mL from 400 mg/kg) and 25% of the acrolein generated by the MTD of CPA & IFOS. No convulsions, neuropathies or renal dysfunction were observed in either specie.
Unlike IFOS/IPM, HOOI is lipophilic, activated intracellular (with &lt; extracellular acrolein and no chloroacetaldehyde released); no IFOS/IPM-associated CNS or GU toxicity was noted. HOOI may increase the safety and efficacy margins of this class of alkylators in advanced CPA- and IFOS-resistant cancers and broaden the target-range (CNS-gliomas). The L-lysine salt stability supports developing HOOI for clinical trials. Supported by grant R44 CA094566 from the NCI/SBIR program.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3222. doi:10.1158/1538-7445.AM2011-3222
Abstract 3229: Thermo-responsive double packaged system for localized drug delivery for cancer treatment
Authors: Williams Eva Christabel , Wiranowska Marzenna , Toomey Ryan , Alcantar Norma 
Published: June 2012

Abstract
This research aims at developing a drug delivery system that will provide a plethora of benefits including cost effectiveness, reduction of toxicity and a control over the release of chemotherapeutics in Ovarian Cancer and Brain Tumor patients. We have designed a drug delivery system consisting of non-ionic surfactant vesicles (niosomes) packaged within a biodegradable, temperature and pH sensitive hydrogel (chitosan) network. Optimization of the release rates were accomplished by altering the molecular weight and cross-link density of the chitosan network and the size of the niosomes. Two chemotherapeutics Paclitaxel and Carboplatin were used for encapsulation. The interaction between niosome and chitosan were observed using Attenuated Total Reflectance- Fourier Transform Infrared (ATR-FTIR) spectroscopy. The drug delivery system was further investigated in human ovarian (OV2008) and human glioma (U373) cell lines. The concentration of the therapeutics used ranged from 0.04-0.4 µg/ml. Confocal imaging of the cells verified that the activity of the drugs remained intact within the niosome-chitosan drug delivery system and cell's toxicity was observed within two hours confirming cellular delivery of the drug. The effect of the niosome-chitosan without the chemotherapeutic drugs on normal cells was also examined indicating that this system is non-toxic. Our results showed that this route of drug delivery to the cancer cells was effective since microtubule stabilization, fragmentation of the nucleus, and condense morphology were noted. Moreover, the time release of the drugs can be finely controlled by varying the crosslinking ratio in the chitosan network from 3:1 (loose network which translates into high release) to 5:1 (tight network which translates into low release). In addition, this system is a liquid solution at room temperature and undergoes a change of phase to a soft, self-containing gel at physiological conditions. The system therefore, can be injected into a tumor site. The materials used to construct this system are low cost and biocompatible and provides a flexible method for drug delivery with applications to intracavitary ovarian cancer and glioma treatment.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3229. doi:10.1158/1538-7445.AM2011-3229
Abstract 3234: Fiber optic-guided photosensitizer drug delivery
Authors: Zamadar Matibur , Ghosh Goutam , Mahendran Adaickapillai , Minnis Mihaela , Kruft Bonnie I. , Kruft Bonnie I. , Ghogare Ashwini , Aebisher David , Greer Alexander 
Published: June 2012

Abstract
A fiber optic device has been developed with a maneuverable probe tip that sparges oxygen gas and photo-detaches pheophorbide (sensitizer) molecules. Singlet oxygen is produced at the probe tip surface which reacts with an alkene bridge causing the release of sensitizer upon fragmentation of a dioxetane intermediate. For optimal sensitizer release the probe tip was loaded with 0.3% sensitizer resulting, where crowding of pheophorbide molecules and self-quenching were kept to a minimum. The fiber optic device delivers pheophorbide molecules and singlet oxygen to discrete locations. Site-selective release of pheophorbide occurred in lipophilic media, it was quantitative in petrolatum (petroleum jelly, 100%), and was inefficient in toluene (5%) and water (&lt;1%) due to poor the solvation. The results open the door to applications in tumor eradication in lipophilic and hypoxic structures requiring cytotoxic control.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3234. doi:10.1158/1538-7445.AM2011-3234
Abstract 3245: Novel anticancer agents – lead discovery and optimization
Authors: Meng Liping , Wang Don-Hong , Wu Chun-Yi , Lam Kit S. 
Published: June 2012

Abstract
Though cancer chemotherapy helps in successful treating some types of solid tumors, lymphomas, and leukemias, cancer is still responsible for about one in every four deaths in the United States nowadays. Thus, it is urgent to develop novel anticancer agents to overcome the problems of toxicity and resistance of existing cancer chemotherapeutic agents, and eventually to cure cancer. Recently we have found some lead compounds possessing anticancer effects through a novel ultra-high-throughput multiplex screening of OBOC (one-bead-one-compound) small molecule combinatorial library against a M13 phage display cDNA expression proteome library derived from T-lymphoma Jurkat cell. These compounds were able to kill both Jurkat cells and HepG2 hepatocarcinoma cells with IC50s ranging from 15 µM to 80 µM. Further biopanning and pull down results showed that some compounds bounded to EIF5B – a eukaryotic translation imitation factor, which might inhibit the cellular translation initiation and result in apoptosis and eventually cause cell death. The lead optimization was carried out by using the method of “methyl walking” and “deletion studies”. A series of novel derivatives have been synthesized and structure-activity relationship will be investigated.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3245. doi:10.1158/1538-7445.AM2011-3245